AIMS: We previously associated acute ST-elevation myocardial infarction (STEMI) with decreased plasma LL-37 levels. Therefore, this study investigated whether plasma LL-37 levels could predict ischemic cardiovascular events in patients after STEMI. METHODS: We prospectively collected peripheral plasma samples and clinical and laboratory data from consecutive patients who presented with STEMI and underwent primary percutaneous coronary intervention at Fuwai Hospital between April and November 2017. Enzyme-linked immunosorbent assay measured plasma LL-37 levels, and we followed the patients for 3 years. Major adverse cardiovascular events (MACEs) were a composite of all-cause mortality, reinfarction, unscheduled revascularization, or ischemic stroke. RESULTS: The study included 302 patients divided into high (≥ median) and low LL-37 level (＜median) groups. The cumulative incidence of MACE (29.1% vs. 12.6%, p=0.0003), all-cause death (12.6% vs. 3.3%, p=0.003), reinfarction (7.1% vs. 2.0%, p=0.04), and unscheduled revascularization (13.0% vs. 5.4%, p=0.04) were higher in the low than those in the high LL-37 level group. Multivariable Cox regression analysis showed that higher LL-37 level independently predicted lower risks of MACE (hazard ratio [HR] 0.390; 95% confidence interval [CI] 0.227-0.669; p＜0.001), all-cause death (HR 0.324; 95%CI 0.119-0.879; p=0.027), and unscheduled revascularization (HR 0.391; 95%CI 0.171-0.907; p=0.027). CONCLUSIONS: High basal plasma level of human LL-37 may predict lower 3-year risks of ischemic cardiovascular events in patients after STEMI.
AIMS: We previously associated acute ST-elevation myocardial infarction (STEMI) with decreased plasma LL-37 levels. Therefore, this study investigated whether plasma LL-37 levels could predict ischemic cardiovascular events in patients after STEMI. METHODS: We prospectively collected peripheral plasma samples and clinical and laboratory data from consecutive patients who presented with STEMI and underwent primary percutaneous coronary intervention at Fuwai Hospital between April and November 2017. Enzyme-linked immunosorbent assay measured plasma LL-37 levels, and we followed the patients for 3 years. Major adverse cardiovascular events (MACEs) were a composite of all-cause mortality, reinfarction, unscheduled revascularization, or ischemic stroke. RESULTS: The study included 302 patients divided into high (≥ median) and low LL-37 level (＜median) groups. The cumulative incidence of MACE (29.1% vs. 12.6%, p=0.0003), all-cause death (12.6% vs. 3.3%, p=0.003), reinfarction (7.1% vs. 2.0%, p=0.04), and unscheduled revascularization (13.0% vs. 5.4%, p=0.04) were higher in the low than those in the high LL-37 level group. Multivariable Cox regression analysis showed that higher LL-37 level independently predicted lower risks of MACE (hazard ratio [HR] 0.390; 95% confidence interval [CI] 0.227-0.669; p＜0.001), all-cause death (HR 0.324; 95%CI 0.119-0.879; p=0.027), and unscheduled revascularization (HR 0.391; 95%CI 0.171-0.907; p=0.027). CONCLUSIONS: High basal plasma level of human LL-37 may predict lower 3-year risks of ischemic cardiovascular events in patients after STEMI.
Authors: Yvonne Döring; Maik Drechsler; Sarawuth Wantha; Klaus Kemmerich; Dirk Lievens; Santosh Vijayan; Richard L Gallo; Christian Weber; Oliver Soehnlein Journal: Circ Res Date: 2012-03-06 Impact factor: 17.367
Authors: Oliver Soehnlein; Sarawuth Wantha; Sakine Simsekyilmaz; Yvonne Döring; Remco T A Megens; Sebastian F Mause; Maik Drechsler; Ralf Smeets; Stefan Weinandy; Fabian Schreiber; Thomas Gries; Stefan Jockenhoevel; Martin Möller; Santosh Vijayan; Marc A M J van Zandvoort; Birgitta Agerberth; Christine T Pham; Richard L Gallo; Tilman M Hackeng; Elisa A Liehn; Alma Zernecke; Doris Klee; Christian Weber Journal: Sci Transl Med Date: 2011-10-05 Impact factor: 17.956
Authors: Borja Ibanez; Stefan James; Stefan Agewall; Manuel J Antunes; Chiara Bucciarelli-Ducci; Héctor Bueno; Alida L P Caforio; Filippo Crea; John A Goudevenos; Sigrun Halvorsen; Gerhard Hindricks; Adnan Kastrati; Mattie J Lenzen; Eva Prescott; Marco Roffi; Marco Valgimigli; Christoph Varenhorst; Pascal Vranckx; Petr Widimský Journal: Eur Heart J Date: 2018-01-07 Impact factor: 29.983
Authors: Joachim Pircher; Thomas Czermak; Andreas Ehrlich; Clemens Eberle; Erik Gaitzsch; Andreas Margraf; Jochen Grommes; Prakash Saha; Anna Titova; Hellen Ishikawa-Ankerhold; Konstantin Stark; Tobias Petzold; Thomas Stocker; Ludwig T Weckbach; Julia Novotny; Markus Sperandio; Bernhard Nieswandt; Alberto Smith; Hanna Mannell; Barbara Walzog; David Horst; Oliver Soehnlein; Steffen Massberg; Christian Schulz Journal: Nat Commun Date: 2018-04-18 Impact factor: 14.919